GlaxoSmithKline: A business on the mend

Fans of a quiet life will not have been impressed by Emma Walmsley’s performance in the two years she has been in the hot seat at GSK. Her predecessor, Sir Andrew Witty, spent 10 years pottering along focused on the group’s consumer health brands and allowing its pharmaceutical arm to lag behind rivals such as AstraZeneca. With her long career at L’Oréal and her lack of pharma experience, many expected Walmsley to follow suit. Instead, she has thrown herself into a radical revitalisation of the company as a whole...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.